FOJTŮ, Michaela, Xinyi CHIA, Zdeněk SOFER, Michal MASAŘÍK and Martin PUMERA. Black Phosphorus Nanoparticles Potentiate the Anticancer Effect of Oxaliplatin in Ovarian Cancer Cell Line. Advanced Functional Materials. Wrinheim: Wiley-VCH Verlag, vol. 27, No 36, p. 1-7. ISSN 1616-301X. doi:10.1002/adfm.201701955. 2017.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Black Phosphorus Nanoparticles Potentiate the Anticancer Effect of Oxaliplatin in Ovarian Cancer Cell Line
Authors FOJTŮ, Michaela (203 Czech Republic, belonging to the institution), Xinyi CHIA (702 Singapore), Zdeněk SOFER (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution) and Martin PUMERA (702 Singapore).
Edition Advanced Functional Materials, Wrinheim, Wiley-VCH Verlag, 2017, 1616-301X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10400 1.4 Chemical sciences
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 13.325
RIV identification code RIV/00216224:14110/17:00095042
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/adfm.201701955
UT WoS 000412319400006
Keywords in English black phosphorus; drug delivery; nanoparticles ovarian; cancer oxaliplatin
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 17:41.
Abstract
During the past few years, growing attention has been paid to black phosphorus (BP) and its unique optical, electrical, and catalytic properties. Furthermore, BP has proven to be biocompatible and biodegradable; qualities that present new opportunities for its utilization in the field of life sciences. However, despite all its suitable properties and applicability, its utilization in biomedicine is still in its infancy. This study reports on the synthesis of black phosphorus nanoparticles (BP NPs) and exploration of thier applicability in targeted drug delivery. BP NPs are loaded with platinum agents—cisplatin and oxaliplatin—and subjected to in vitro evaluation of targeted drug delivery. The BP NPs are not only able to load the investigated platinum derivatives on their surfaces, but also to transfer the therapeutic cargo to target specific tissue and to combine their effect with oxaliplatin, which leads to further potentiation of the anticancer effect.
Links
GA16-05961S, research and development projectName: Pokročilé nosiče platinových léčiv
Investor: Czech Science Foundation
MUNI/A/1355/2016, interní kód MUName: Kardiovaskulární systém očima molekulární fyziologie
Investor: Masaryk University, Category A
ROZV/24/LF/2016, interní kód MUName: LF - Příspěvek IP 2016
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 20/4/2024 02:38